Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model.

Robertson GT, Ektnitphong VA, Scherman MS, McNeil MB, Dennison D, Korkegian A, Smith AJ, Halladay J, Carter DS, Xia Y, Zhou Y, Choi W, Berry PW, Mao W, Hernandez V, Alley MRK, Parish T, Lenaerts AJ.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02071-18. doi: 10.1128/AAC.02071-18. Print 2019 Apr.

2.

Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis.

Jacobs RT, Lunde CS, Freund YR, Hernandez V, Li X, Xia Y, Carter DS, Berry PW, Halladay J, Rock F, Stefanakis R, Easom E, Plattner JJ, Ford L, Johnston KL, Cook DAN, Clare R, Cassidy A, Myhill L, Tyrer H, Gamble J, Guimaraes AF, Steven A, Lenz F, Ehrens A, Frohberger SJ, Koschel M, Hoerauf A, Hübner MP, McNamara CW, Bakowski MA, Turner JD, Taylor MJ, Ward SA.

J Med Chem. 2019 Mar 14;62(5):2521-2540. doi: 10.1021/acs.jmedchem.8b01854. Epub 2019 Feb 26.

3.

Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA.

Xia Y, Zhou Y, Carter DS, McNeil MB, Choi W, Halladay J, Berry PW, Mao W, Hernandez V, O'Malley T, Korkegian A, Sunde B, Flint L, Woolhiser LK, Scherman MS, Gruppo V, Hastings C, Robertson GT, Ioerger TR, Sacchettini J, Tonge PJ, Lenaerts AJ, Parish T, Alley M.

Life Sci Alliance. 2018 Jun 1;1(3):e201800025. doi: 10.26508/lsa.201800025. eCollection 2018 Jun.

4.

Evaluation of amide replacements in CCR5 antagonists as a means to increase intrinsic permeability. Part 2: SAR optimization and pharmacokinetic profile of a homologous azacyle series.

Wanner J, Chen L, Lemoine RC, Kondru R, Jekle A, Heilek G, deRosier A, Ji C, Berry PW, Rotstein DM.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6802-7. doi: 10.1016/j.bmcl.2010.08.118. Epub 2010 Sep 18.

PMID:
20855212
5.

Identification of glutathione-derived metabolites from an IP receptor antagonist.

Fitch WL, Berry PW, Tu Y, Tabatabaei A, Lowrie L, Lopez-Tapia F, Liu Y, Nitzan D, Masjedizadeh MR, Varadarajan A.

Drug Metab Dispos. 2004 Dec;32(12):1482-90. Epub 2004 Sep 15.

PMID:
15371298
6.

Selective inhibition of mammalian lanosterol 14 alpha-demethylase by RS-21607 in vitro and in vivo.

Swinney DC, So OY, Watson DM, Berry PW, Webb AS, Kertesz DJ, Shelton EJ, Burton PM, Walker KA.

Biochemistry. 1994 Apr 19;33(15):4702-13.

PMID:
8161528
7.

Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.

Walker KA, Kertesz DJ, Rotstein DM, Swinney DC, Berry PW, So OY, Webb AS, Watson DM, Mak AY, Burton PM, et al.

J Med Chem. 1993 Jul 23;36(15):2235-7. No abstract available.

PMID:
8340925
8.

Dermal absorption of lonapalene, a new anti-psoriatic drug.

Berry PW, Tomlinson RV, Bowen JL.

Proc West Pharmacol Soc. 1987;30:137-9. No abstract available.

PMID:
3628265

Supplemental Content

Loading ...
Support Center